Head-to-head evidence
Brivaracetam vs Levetiracetam (Elepsia XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Synaptic vesicle glycoprotein 2A (SV2A) · full Epilepsy pipeline
Brivaracetam
Marketed by UCB
NCT04666610 · Phase 3 · completed
The trial randomized 153 participants and used quadruple masking with placebo control, with absence-seizure freedom measured by 24-hour EEG as the primary clinical endpoint. Because the registry has no posted results, whether the primary endpoint was met is unknown, supporting a moderate evidence grade rather than a strong one.
Next expected readout: November 2029 · NCT06315322 (registry estimate)
Levetiracetam (Elepsia XR)
Marketed by Sun Pharma Advanced Research Company Limited
NCT01150331 · Phase 3 · completed
Randomized active-controlled study in status epilepticus published in Lancet Neurology 2016.
Next expected readout: June 2029 · NCT06907173 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brivaracetam's landscape · Levetiracetam (Elepsia XR)'s landscape